This legislation aims to enhance the Medicare payment system for skin substitute products used in advanced wound care while improving the regulation and approval processes for these products and human cellular and tissue-based products. The goal is to ensure adequate coverage and reimbursement under Medicare, thereby increasing patient access to necessary treatments while maintaining safety and efficacy. Key provisions include the formal inclusion of skin substitute products in Medicare coverage, with a new payment structure set to begin on January 1, 2026.